Daiwa Securities Group Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 6.2% during the 4th quarter, HoldingsChannel reports. The fund owned 45,056 shares of the medical research company’s stock after selling 2,997 shares during the period. Daiwa Securities Group Inc.’s holdings in IQVIA were worth $10,156,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the stock. Claret Asset Management Corp increased its stake in IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after buying an additional 49 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. increased its stake in IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after buying an additional 58 shares during the period. Brookstone Capital Management increased its stake in IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after buying an additional 63 shares during the period. Private Advisor Group LLC increased its stake in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the period. Finally, Keybank National Association OH increased its stake in IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after buying an additional 67 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Morgan Stanley set a $225.00 price target on IQVIA in a research report on Thursday, May 7th. Evercore reissued an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their target price for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, Mizuho set a $215.00 target price on shares of IQVIA in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $224.13.
IQVIA Trading Down 1.8%
NYSE IQV opened at $183.56 on Friday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The company has a market capitalization of $30.64 billion, a price-to-earnings ratio of 22.75, a price-to-earnings-growth ratio of 1.57 and a beta of 1.21. The company’s 50-day simple moving average is $172.12 and its two-hundred day simple moving average is $194.94. IQVIA Holdings Inc. has a one year low of $147.62 and a one year high of $247.04.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the business earned $2.70 EPS. The company’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.
IQVIA announced that its board has authorized a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Articles
- Five stocks we like better than IQVIA
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
